SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.276
AS - Asia 5.442
EU - Europa 3.510
SA - Sud America 798
AF - Africa 82
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 22.122
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.022
SG - Singapore 2.237
CN - Cina 1.630
DE - Germania 779
BR - Brasile 678
UA - Ucraina 620
IT - Italia 524
HK - Hong Kong 460
GB - Regno Unito 421
TR - Turchia 407
FI - Finlandia 343
VN - Vietnam 321
SE - Svezia 179
RU - Federazione Russa 150
CA - Canada 125
PL - Polonia 112
MX - Messico 105
FR - Francia 97
ID - Indonesia 89
IN - India 82
AT - Austria 62
AR - Argentina 54
JP - Giappone 52
BE - Belgio 51
ES - Italia 46
ZA - Sudafrica 45
BD - Bangladesh 43
NL - Olanda 42
LT - Lituania 27
IQ - Iraq 22
PK - Pakistan 17
EC - Ecuador 15
CO - Colombia 14
EG - Egitto 12
PE - Perù 12
IR - Iran 11
CZ - Repubblica Ceca 9
NO - Norvegia 9
VE - Venezuela 9
AU - Australia 8
BG - Bulgaria 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
KE - Kenya 7
MA - Marocco 7
SA - Arabia Saudita 7
CL - Cile 6
IE - Irlanda 6
PY - Paraguay 6
JO - Giordania 5
AZ - Azerbaigian 4
CH - Svizzera 4
CR - Costa Rica 4
HN - Honduras 4
KG - Kirghizistan 4
NP - Nepal 4
PH - Filippine 4
RO - Romania 4
AL - Albania 3
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
KZ - Kazakistan 3
LV - Lettonia 3
PA - Panama 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BO - Bolivia 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
HR - Croazia 2
KH - Cambogia 2
KR - Corea 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
KY - Cayman, isole 1
LK - Sri Lanka 1
MY - Malesia 1
NI - Nicaragua 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 22.118
Salva come PNG Salva come JPEG
Città #
Ashburn 1.421
Singapore 1.355
Fairfield 1.266
Woodbridge 1.234
Houston 700
Jacksonville 672
Chandler 666
Beijing 632
Santa Clara 579
Ann Arbor 517
Seattle 485
Hong Kong 457
Wilmington 450
Cambridge 415
Munich 365
Dallas 265
Izmir 237
Los Angeles 184
Nanjing 173
Ferrara 167
Princeton 165
New York 164
Helsinki 142
San Diego 114
Boardman 105
Warsaw 103
Ho Chi Minh City 102
Shanghai 100
Milan 90
Hanoi 71
Jakarta 70
Bremen 66
São Paulo 66
Mexico City 62
London 60
Turku 58
Shenyang 57
Brussels 50
Falls Church 48
Tokyo 48
Brooklyn 47
Hebei 45
Hefei 45
The Dalles 45
Vienna 45
Tianjin 44
Montreal 43
Moscow 43
Chicago 42
Buffalo 41
Orem 41
Denver 39
Atlanta 38
Nanchang 38
Frankfurt am Main 37
Boston 36
Stockholm 32
Toronto 32
Changsha 31
Jiaxing 29
Norwalk 29
Poplar 29
Chennai 28
Johannesburg 27
San Mateo 25
Washington 25
Auburn Hills 24
San Francisco 24
San Jose 24
Ankara 23
Jinan 22
Rio de Janeiro 22
Mountain View 21
Falkenstein 20
Phoenix 20
Redwood City 20
Manchester 19
Council Bluffs 18
Rome 18
Dearborn 17
Zhengzhou 17
Biên Hòa 16
Brasília 16
Da Nang 16
Querétaro 16
Amsterdam 15
Charlotte 15
Guangzhou 15
Ottawa 15
Belo Horizonte 14
Haiphong 14
Orange 14
Leawood 13
Mcallen 13
New Delhi 13
Secaucus 13
Augusta 12
Lappeenranta 12
Montréal 12
Nuremberg 12
Totale 15.512
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 347
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 338
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 281
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 241
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 235
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 230
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 227
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 224
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 221
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 213
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 206
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 204
5‐Hydroxytryptamine‐mediated effects of nicotine on endogenous GABA efflux from guinea‐pig cortical slices 203
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 203
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 203
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 196
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 194
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 194
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 192
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 192
Loss of cortical GABA terminals in Unverricht–Lundborg disease 190
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 186
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 184
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 184
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 183
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 182
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 181
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 180
Antagonisti dei recettori NOP e loro usi terapeutici 178
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 178
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 176
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 176
Role of LRRK2 in the regulation of dopamine receptor trafficking 176
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 175
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 175
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 175
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 175
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 173
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 173
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 173
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 173
Autophagy and LRRK2 in the Aging Brain 173
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]‐d‐aspartate and endogenous GABA in freely moving guinea‐pigs 172
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 171
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 170
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 170
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 167
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 167
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 166
NOP receptor ligands and Parkinson’s disease 165
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 165
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 164
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 162
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 162
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 161
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 160
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 160
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 159
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 159
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 157
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 154
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 153
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 152
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 152
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 150
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 149
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 149
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 146
Parkinson's disease: no NOP, new hope 146
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 144
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 143
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 143
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 139
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 137
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat 135
Managing Parkinson's disease: moving ON with NOP 135
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 134
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 134
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 134
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 133
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 132
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 132
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 129
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 128
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 128
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 128
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 125
Synthesis and structure activity relationships of delthorphine analogues 121
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 118
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 118
Nociceptin/orphanin FQ modulates neurotransmitter release in the substantia nigra: Biochemical and behavioural outcome 118
NR2A and NR2B Subunit Selective NMDA antagonists improve motor performance and reduce pallidal GABA release in 6-OHDA hemilesioned rats 117
Nociceptin/orphanin FQ receptor antagonists reverse parkinsonism in MPTP-treated mice and non-human primates 116
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 116
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 116
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 116
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 115
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 114
null 113
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 112
Totale 16.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.232
Totale 108.591
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.239 0 0 0 0 0 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20253.708 74 88 310 82 402 505 146 204 569 373 528 427
2025/20266.087 1.178 343 893 1.354 1.681 638 0 0 0 0 0 0
Totale 22.339